New regulatory framework expands industrial opportunities and requires structured health governance
The Brazilian Health Regulatory Agency (Anvisa) has approved a resolution authorizing, under restricted criteria, the cultivation of Cannabis sativa by duly qualified legal entities, exclusively for medicinal or pharmaceutical purposes, with a THC limit of up to 0.3%.
The regulation complies with a determination of the Superior Court of Justice (STJ) to regulate medicinal cultivation in Brazil and broadens the scope for the use and commercialization of cannabis-based products, including:
- Sale of cannabidiol (CBD) in compounding pharmacies
- New routes of administration (buccal, sublingual, and dermatological)
- Expansion of the patient profile eligible for treatment with medicines containing THC levels above 0.2%
The prohibition of recreational use remains unchanged.
Reconfiguration of the regulatory environment
The sector will now operate under a regulated industrialization model within Brazil, requiring technical, sanitary, and legal structures aligned with strict oversight and compliance standards.
Corporate cultivation authorization will depend on:
- Prior licensing with Anvisa
- Production traceability controls
- Continuous monitoring of THC levels
- Full compliance with Good Manufacturing Practices (GMP)
- Implementation of pharmacovigilance protocols
Regulatory governance is no longer peripheral; it becomes a central pillar of the business model.
Risks and market implications
The new framework may lead to:
- Reorganization of the production chain
- Increased competitive pressure on importing companies
- Need for contractual and corporate restructuring
- Adjustments to labeling and restricted advertising policies
- Intensified sanitary inspections and enforcement
Operating in this sector now requires strong integration among:
- Legal
- Regulatory
- Compliance
- Pharmaceutical
- Risk management functions
Strategic recommendations
Companies seeking to enter or expand in this market should consider:
- Detailed regulatory mapping and feasibility analysis
- Implementation of integrated health governance structures
- Review of contracts with suppliers and strategic partners
- Update of internal policies and pharmacovigilance protocols
- Assessment of technical and scientific partnerships
Proactive strategic planning tends to reduce administrative contingencies and mitigate reputational exposure.
Multidisciplinary integration as a competitive advantage
Structuring operations in the medicinal cannabis sector demands a multidisciplinary approach involving:
- Regulatory – engagement with Anvisa and assessment of sanitary requirements
- Corporate Contracts – structuring production chains and strategic agreements
- Corporate and M&A – organization of investments, corporate structures, and joint ventures
- Compliance and Corporate Investigations – mitigation of operational and regulatory risks
- Intellectual Property – protection of trademarks and intangible assets
At PDK Advogados, we closely monitor regulatory developments in highly regulated industries, delivering integrated strategic analysis for businesses that require legal certainty and institutional predictability.
To understand the specific impacts of this new regulatory framework on your sector or business model, our team remains available to provide a tailored and in-depth technical assessment.
